Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway

CDK4/6 inhibitors (CDK4/6i) are effective in breast cancer, however drug resistance is frequently encountered and poorly understood. We conducted a genomic analysis of 348 estrogen receptor-positive breast cancers treated with CDK4/6i and identified loss of function mutations affecting FAT1 and RB1...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell
Main Authors: Li, Zhiqiang, Razavi, Pedram, Li, Qing, Toy, Weiyi, Liu, Bo, Ping, Christina, Hsieh, Wilson, Sanchez-Vega, Francisco, Brown, David N., Paula, Arnaud F. Da Cruz, Morris, Luc, Selenica, Pier, Eichenberger, Emily, Shen, Ronglai, Schultz, Nikolaus, Rosen, Neal, Scaltriti, Maurizio, Brogi, Edi, Baselga, Jose, Reis-Filho, Jorge S., Chandarlapaty, Sarat
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6294301/
https://ncbi.nlm.nih.gov/pubmed/30537512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2018.11.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados